IRVINE, Calif., Nov. 3, 2014 (GLOBE NEWSWIRE) -- Endologix, Inc. (Nasdaq:ELGX), developer and marketer of innovative treatments for aortic disorders, announced today details for its 2014 investor meeting, which will be held on November 20, 2014 from 5:00 to 7:30 pm ET at the New York Hilton Midtown. The event will include a Company update, presentations from prominent physicians and a question and answer session with the physicians and Endologix management
|Event:||Endologix Investor Meeting|
|Date:||November 20, 2014|
|Time:||5:00 to 7:30 pm ET (registration and refreshments begin at 5:00 pm ET; formal presentation begins at 5:30 pm ET)|
|Location:||Madison Suite, New York Hilton Midtown|
|1335 Avenue of the Americas, New York, NY|
|Physician Speakers:||* Professor Matthew Thompson, MD, St. Georges Vascular Institute, London|
|* Andrew Holden, MD, Associate Professor of Radiology at Auckland Hospital|
|* Christopher J. Kwolek, MD, Director, Vascular and Endovascular Training program at the Massachusetts General Hospital and Chief of Vascular Surgery at Newton Wellesley Hospital in Boston|
A live audio webcast of the investor meeting will be available by visiting the investor relations section of Endologix's website at www.endologix.com. Participants are encouraged to log on at a few minutes prior to 5:30 pm ET in order to download any applicable audio software. A replay of the presentation will be available within 24 hours and will be available for 30 days.
Please RSVP by contacting Brandon Vazquez at The Ruth Group at: firstname.lastname@example.org or 646-536-7032 by November 14, 2014.
About Endologix, Inc.
Endologix, Inc. develops and manufactures minimally invasive treatments for aortic disorders. Endologix focus is endovascular stent grafts for the treatment of abdominal aortic aneurysms (AAA). AAA is a weakening of the wall of the aorta, the largest artery in the body, resulting in a balloon-like enlargement. Once AAA develops, it continues to enlarge and, if left untreated, becomes increasingly susceptible to rupture. The overall patient mortality rate for ruptured AAA is approximately 80%, making it a leading cause of death in the U.S. Additional information can be found on Endologix's website at www.endologix.com.
CONTACT: COMPANY CONTACT: Endologix, Inc. John McDermott, CEO Shelley Thunen, CFO (949) 595-7200 www.endologix.com INVESTOR CONTACTS: The Ruth Group Nick Laudico (646) 536-7030 Zack Kubow (646) 536-7020Source:Endologix